Home Cart Sign in  
Chemical Structure| 94497-51-5 Chemical Structure| 94497-51-5

Structure of Tamibarotene
CAS No.: 94497-51-5

Chemical Structure| 94497-51-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tamibarotene is an agonist of retinoic acid receptor α (RARα) with ED50 of 0.79 nM that can induce differentiation and apoptosis of HL-60 cells.

Synonyms: Am 80; Amnolake; SY-1425

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Banse, Stephen A ; Coleman-Hulbert, Anna L ; Sedore, Christine A ; Johnson, Erik ; Lithgow, Gordon J ; Driscoll, Monica , et al.

Abstract: The Caenorhabditis Intervention Testing Program recently characterized the longevity-promoting effects of the vitamin A derivative all-trans retinoic acid (atRA). Here, we test two atRA-related compounds, tamibarotene and bakuchiol, for longevity effects in three strains of Caenorhabditis species. Both tamibarotene, a potent RAR agonist, and bakuchiol, a meroterpene derived from Psoralea corylifolia, showed no significant increase in lifespan across a dosage range of six concentrations. Additionally, bakuchiol was broadly toxic at higher doses. These findings highlight the specificity of atRA's longevity effects and suggest that compounds related to atRA may not universally promote lifespan extension.

Purchased from AmBeed: ;

Alternative Products

Product Details of Tamibarotene

CAS No. :94497-51-5
Formula : C22H25NO3
M.W : 351.44
SMILES Code : C1=CC(=CC2=C1C(CCC2(C)C)(C)C)NC(C3=CC=C(C=C3)C(O)=O)=O
Synonyms :
Am 80; Amnolake; SY-1425
MDL No. :MFCD00866188
InChI Key :MUTNCGKQJGXKEM-UHFFFAOYSA-N
Pubchem ID :108143

Safety of Tamibarotene

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02807558 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 2 Recruiting December 2021 United States, Iowa ... More >> Recruiting Iowa City, Iowa, United States United States, Massachusetts Recruiting Boston, Massachusetts, United States United States, Michigan Recruiting Ann Arbor, Michigan, United States United States, New York Recruiting New York, New York, United States Recruiting Rochester, New York, United States United States, North Carolina Recruiting Durham, North Carolina, United States United States, Ohio Recruiting Cleveland, Ohio, United States United States, Oregon Recruiting Portland, Oregon, United States United States, Pennsylvania Recruiting Pittsburgh, Pennsylvania, United States United States, Tennessee Recruiting Nashville, Tennessee, United States United States, Texas Recruiting Houston, Texas, United States France Centre Hospitalier Universitaire Nancy Recruiting Vandoeuvre les nancy, France, 54511 Institut Gustave Roussy Recruiting Villejuif, France, 94805 Less <<
NCT00417391 Crohn's Disease Phase 2 Completed - Japan ... More >> Toyohashi, Aichi, Japan Sakura, Chiba, Japan Sapporo, Hokkaido, Japan Nishinomiya, Hyogo, Japan Fujisawa, Kanagawa, Japan Nakagami, Okinawa, Japan Otsu, Shiga, Japan Shinjuku, Tokyo, Japan Less <<
NCT01226147 Lupus Nephritis PHASE2 UNKNOWN 2025-02-13 Kinki University Hospital, Osa... More >>ka, 5898511, Japan Less <<
NCT00985530 Acute Promyelocytic Leukemia Phase 1 Terminated(Supporting agency w... More >>ithdrew funding for study.) Less << - United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 Less <<
NCT01343355 HTLV-I-Associated Myelopathy PHASE2|PHASE3 UNKNOWN 2025-03-12 Iseikai Medical Corporation, S... More >>hoyo Kashiwadai Hospital, Kanagawa, 243-0402, Japan Less <<
NCT00520208 Acute Promyelocytic Leukemia PHASE2 COMPLETED 2025-01-13 Northwestern University, Chica... More >>go, Illinois, 60611, United States|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01120002 Alzheimer's Disease Phase 2 Unknown December 2012 Japan ... More >> Osaka City University Hospital Recruiting Osaka, Japan, 545-8586 Contact: Center for Drug&Food Clinical Evaluation    +81-6-6645-344    morikka@med.osaka-cu.ac.jp Less <<
NCT01337154 Stage IIIB Non-small Cell Lung... More >> Cancer With Pleural Effusion Stage IV Non-small Cell Lung Cancer Less << Phase 2 Terminated(Interim analysis sh... More >>owed that the primary endpoint would not be met.) Less << - United States, California ... More >> Desert Hematology Oncology Medical Group, Inc. Rancho Mirage, California, United States, 92270 United States, Kansas Kansas City Cancer Center Kansas City, Kansas, United States, 66112 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Bulgaria Department of Medical Oncology, Specialized Hospital for Active Treatment of Oncological Diseases Sofia, Bulgaria, 1233 Medical Oncology Clinic, Multiprofile Hospital for Active Treatment Varna, Bulgaria, 9010 Department of Medical Oncology, Complex Oncology Center Veliko Tarnovo, Bulgaria, 5000 India NIZAM's Institute of Medical Sciences Hyderabad, Andhra Pradesh, India, 500082 M S Patel Cancer Centre, Shree Krishna Hospital Anand, Gujarat, India, 388 325 Curie Manavata Cancer Centre Nashik, Maharashtra, India, 411013 Shatabdi Super Speciality Hospital Nashik, Maharashtra, India, 422 005 Noble Hospital Pune, Maharashtra, India, 411013 Dr. Kamakshi Memorial Hospital Chennai, Pallikaranai, India, 600100 G Kuppuswamy Naidu Memorial Hospital, Valvadi Narayanaswamy Cancer Centre Coimbatore, Pappanaickenpalayam, India, 641037 Orchid Nursing Home Kolkata, West Bengal, India, 700054 Mexico Instituto Nacional de Cancerologia Mexico City, Mexico Russian Federation State Medical Institution: Arkhangelsk Regional Clinical Oncology Center Arkhangelsk, Russian Federation, 163045 State Therapeutical and Prophylatic Institution: Chelyabinsk Regional Clinical Oncology Center Chelyabinsk, Russian Federation, 454087 State Medical Instituion Kursk Regional Oncology Center Kursk, Russian Federation, 305035 Non-State Medical Institution: Central Clinical Hospital #2 Moscow, Russian Federation, 129128 St. Petersburg State Healthcare Institution: City Clinical Oncology Center Saint-Pertersburg, Russian Federation, 197022 Ukraine Public Institution: Dnipropetrovsk City Multispeciality Clinical Hospital #4 Dnipropetrovsk, Ukraine, 49102 Public Clinical Treatment and Prophylaxis Instituion: Donetsk Regional Antitumor Center Donetsk, Ukraine, 83092 Ivano-Frankivsk Regional Oncology Center Ivano-Frankivsk, Ukraine, 76018 Public Healthcare Instituion: Kharkiv Regional Clinical Oncology Center Kharkiv, Ukraine, 61070 Kyiv City Clinical Oncology Center Kyiv, Ukraine, 03115 Zakarpattia Regional Clinical Oncology Center Uzhhorod, Ukraine, 88014 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.28mL

14.23mL

2.85mL

1.42mL

28.45mL

5.69mL

2.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories